Abcam, ab301140, Human PDE5A knockout A549 cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
PDE5A KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Form:LiquidSee storage information,
Knockout validation:Next Generation Sequencing,
Disease:Carcinoma

Product details:
Although we aim to provide customers with a homozygous clone, feasibility will be dependent on the biology of the protein. Should only heterozygous edits be achieved, you will be notified of the outcome and be asked to confirm whether the cell line is acceptable. All clones will be accompanied with DNA sequencing data, and the mutation description.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-PDE5A, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PDE5A also known as PDE5 or phosphodiesterase type 5 plays a critical role in hydrolyzing cyclic guanosine monophosphate (cGMP) to its inactive form. This enzyme is part of the phosphodiesterase family and has a molecular mass of approximately 100 kDa. PDE5A is expressed mainly in the smooth muscle cells of blood vessels and in the corpus cavernosum of the penis. Other expression sites include the lung heart and skeletal muscle.
Biological function summary
PDE5A regulates intracellular levels of cGMP an important secondary messenger in various signaling pathways. It is not part of a large protein complex but directly influences the contractility of smooth muscle tissues. By controlling cGMP levels PDE5A modulates vascular tone and influences processes such as vasodilation. This regulation is essential for maintaining a balance in the contractile state of muscles impacting blood flow and other vital functions.
Pathways
PDE5A contributes significantly to the nitric oxide (NO)-cGMP signaling pathway which is important for vascular relaxation. In this pathway nitric oxide stimulates guanylate cyclase to produce cGMP which then activates specific kinases and ion channels. Related proteins such as guanylate cyclase and cGMP-dependent protein kinases work alongside PDE5A to mediate smooth muscle relaxation and vasodilation particularly in penile erectile tissue.
PDE5A shows strong connections to erectile dysfunction and pulmonary hypertension. In the case of erectile dysfunction impaired regulation of cGMP by PDE5A affects the relaxation of smooth muscle leading to inadequate blood flow. Pulmonary hypertension involves elevated blood pressure in the lung arteries which PDE5A influences through its role in controlling vascular tone. The enzyme guanylate cyclase associates closely with PDE5A in these contexts as both influence cGMP pathways involved in these conditions.